YIH
BTAI icon

Y-Intercept (HK)’s BioXcel Therapeutics BTAI Stock Holding History

Y-Intercept (HK)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,683
Closed -$95.9K – 1334
2024
Q2 		$95.9K Buy
+4,683
New +$157K 0.01% 1262
2023
Q4 		– Sell
-1,722
Closed -$69.7K – 1255
2023
Q3 		$69.7K Buy
+1,722
New +$174K 0.01% 985

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Y-Intercept (HK)'s BTAI Position: Q3 2024 in Review

Y-Intercept (HK) sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 4,683 shares — an estimated $95.9K sold.

Y-Intercept (HK) first reported a position in BTAI in Q3 2023 and held it in 2 quarters. The position peaked at $95.9K in Q2 2024. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Y-Intercept (HK) reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 4,683 BioXcel Therapeutics shares in Q3 2024, an estimated $95.9K.
  • Y-Intercept (HK) first reported a position in BioXcel Therapeutics in Q3 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s BioXcel Therapeutics position peaked at $95.9K in Q2 2024.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.